Deprecated: Function eregi() is deprecated in /mnt/stor18-wc2-dfw1/415940/739962/www.biomedreports.com/web/content/administrator/components/com_sefservicemap/include/pingback.class.php on line 101

Deprecated: Function eregi() is deprecated in /mnt/stor18-wc2-dfw1/415940/739962/www.biomedreports.com/web/content/administrator/components/com_sefservicemap/include/pingback.class.php on line 107
ImmunoCellular Therapeutics shares rocket on heavy volume | Home Page | BioMedReports.Com

ImmunoCellular Therapeutics shares rocket on heavy volume

Print E-mail
By M.E.Garza   
Tuesday, 31 January 2012 06:52
FDA CalendarTrading volume for shares of ImmunoCellular Therapeutics (OTCBB:IMUC) has been on the rise during the past few sessions.

The biotechnology company focused on developing new therapeutics to fight cancer using the immune system saw 755,068 shares trade hands during Monday's regular session—more than three times the daily average. Shares closed at 1.55 +0.20 (up 14.81%) when the closing bell rang, but headed higher after hours to close at $1.61 +0.06 (3.87%).

Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach

Immunocellular: Pipeline Potential And Institutional Interest Fuel Rebound

Although details are sketchy, speculators appear to be taking positions in the stock ahead of either pending developments or some kind of announcement. The only official word from the firm came earlier in the day when a news release informed investors that its president and CEO, Manish Singh Ph.D., was scheduled to present at the Immunotherapeutics Partnering and Deal Making Conference, currently taking place in San Diego, California.

Dr. Singh's presentation titled "Targeting Cancer Stem Cells Via Immunotherapy" and was to include an overview of ImmunoCellular's clinical activities to date including ICT-107, its lead program targeting cancer stem cells (CSC) in Glioblastoma. ICT-107 is currently in a randomized phase II clinical trial at multiple centers in the US. Company is also developing two additional products targeting CSCs in tumors via modulating immune system.

ICT107 is a new generation dendritic cell-based therapeutic vaccine that consists of a number of specific tumor antigens which, when loaded onto the dendritic cells, are expected to stimulate the body's T cells to target only these specific proteins on the patient's tumor cells. This is accomplished by extracting dendritic cells from a patient, loading them with the antigens, and reintroducing them to the patient's body to trigger an immune response. ICT107 is being developed in the form of intradermal injection as a therapeutic vaccine for glioblastoma multiforme.

Shares nearly touched the 200 day moving average before pulling back in afternoon trading.  Prices for the equity are currently -39.22 % from their previous 52-Wk High ($ 2.55). Shares had traded down briefly following a financing on January 10, 2012 from which the company received net proceeds of approximately $9.4 million.





Disclosure: None




BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter

BioMedReports Trigger for stress processes discovered in the brain. http://t.co/jAyTM3PIP1
13hreplyretweetfavorite
BioMedReports We here at http://t.co/Gh1Gn5YCuz wish you and your family a safe and Happy Thanksgiving. http://t.co/FCbSNKrVuj
BioMedReports This is how a living, beating heart is grown from stem cells. http://t.co/MLrFZyj3la
Benzinga.com supporter Seeking Alpha Certified